Favorable Responses Derived From Trastuzumab Deruxtecan in HER2+ NSCLC


Trastuzumab deruxtecan demonstrates clinically meaningful benefit in patients with non¬–small cell lung cancer harboring HER2 mutations, according to results from the DESTINY-Lung02 trial.

Interim results of the DESTINY-Lung02 trial (NCT04644237) were presented the 2022 European Society for Medical Oncology Congress (ESMO) and showed a clinically meaningful benefit to and favorable safety profile with the lower of 2 doses of trastuzumab deruxtecan (Enhertu) for the treatment of patients with HER2-mutated non–small cell lung cancer.1

The blinded, non-comparative phase 2 trial assessed trastuzumab deruxtecan at 5.4 mg/kg and 6.4 mg/kg every 3 weeks, randomly assigning patients 2:1 to receive the lower dose versus the higher dose. The confirmed overall response rate (cORR) in the prespecified early cohort (PEC) of the study was 53.8% (95% CI, 39.5%-67.8%) at the lower dose level and 42.9% (95% CI, 24.5%-62.8%) at the higher dose level. The lower dose also showed superior safety and tolerability, including a lower rate of interstitial lung disease (ILD).

“The safety profile was generally consistent with the established safety profile of trastuzumab deruxtecan, [but] the patients in the 5.4 mg/kg arm experienced a lower frequency of grade 3 or more drug-related AEs [adverse events] and experienced lower drug discontinuation, dose reduction, and drug interruption,” stated Koichi Goto, MD, in his presentation at the 2022 ESMO Congress.

The DESTINY-Lung01 trial (NCT03505710) showed efficacy of this agent at the 6.4 mg/kg dose in patients with previously treated HER2-mutant NSCLC.2 Now the DESTINY-Lung02 trial is investigating the benefit-risk profile of 2 dose levels. The primary end point was cORR by blinded independent central review, while the secondary end points included investigator-assessed cORR, duration of response (DOR), disease control rate (DCR), progression-free survival, overall survival, and safety and tolerability.1

Enrolled patients must have had metastatic NSCLC with a confirmed HER2 mutation. They needed to have undergone prior treatment including platinum-based chemotherapy and were excluded if they had prior or current non-infectious ILD.

At a data cutoff of March 24, 2022, 52 patients in the PEC assigned to receive 5.4 mg/kg of trastuzumab deruxtecan and 28 assigned to 6.4 mg/kg were assessed. This cohort was randomized 4.5 months or earlier before the interim analysis cutoff to provide a better efficacy assessment. In the safety analysis set, 101 were assigned to receive 5.4 mg/kg and 50 were assigned to receive 6.4 mg/kg.

In the 5.4 mg/kg arm of the PEC, there were 27 (51.9%) partial responses (PR), 1 (1.9%) complete response (CR), 19 (36.5%) patients with stable disease (SD), 2 (3.8%) with progressive disease (PD), and 3 (5.8%) who were not estimable (NE). In the 6.4 mg/kg arm, there were 11 (39.3%) PR, 1 (3.6%) CR, 14 (50.0%) SD, 1 (3.6%) PR, and 1 (3.6%) NE.

There were 47 patients (90.4%; 95% CI, 79.0%-96.8%) with a confirmed DCR for the lower-dose arm and 26 (92.9%; 95% CI, 76.5%-99.1%) in the higher-dose arm. The median DOR was NE (4.2 months–NE) and 5.9 months (2.8–NE) for the lower- and higher-dose arms, respectively.

An additional analysis of the response at a data cutoff of June 22, 2022, showed the median DOR was 8.7 months (95% CI, 7.1–NE) and the cORR was 57.7% (95% CI, 43.2%-71.3%) for the 5.4 mg/kg arm.

In terms of safety and tolerability, the rate of any-grade treatment-emergent adverse events (TEAEs) was 92.1% for the patients receiving the lower-dose and 100% for those receiving the higher dose. For grade 3 or higher TEAEs, it was 31.7% versus 58.0%, respectively. Dose reductions associated with TEAEs occurred in 9.9% of the patients in the lower-dose arm, dose discontinuation occurred in 7.9% of this arm, and dose interruption occurred in 13.9%. In the higher-dose arm, the rate of dose reductions due to TEAEs was 26.0%, the rate of dose discontinuations was 16.0%, and the rate of dose interruptions was 30.0%.

ILD, a TEAE of interest, occurred in 5.9% of the lower-dose arm versus 14.0% in the higher-dose arm. In addition, the median duration of treatment was shorter for the higher-dose arm: 4.7 months versus 5.5 months in the PEC and 3.3 months versus 3.7 months in the safety population.

Based on data from this trial, the FDA recently approved the 5.4 mg/kg dose for this patient population.3

“The totality of the evidence and positive benefit-risk balance supported the FDA’s approval of trastuzumab deruxtecan at 5.4 mg/kg, as the first HER2-targeted treatment for patients [with] previously treated HER2-mutated NSCLC and supports the establishment of trastuzumab deruxtecan as their new standard of care in this population,” Goto concluded.1


  1. Goto K, Sang-We K, Kubo T, et al. LBA55 - Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. Ann Oncol. 2022;33(suppl 7):LBA55. doi:10.1016/annonc/annonc1089
  2. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241-251. doi:10.1056/NEJMoa2112431
  3. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. FDA. August 11, 2022. Accessed September 11, 2022. https://bit.ly/3xbRWTe
Related Videos
Alexander I. Spira, MD, PhD, FACP, an expert on lung cancer
Alexander I. Spira, MD, PhD, FACP, an expert on lung cancer
Cell therapy and vaccine approaches are among the several potential options for targeting KRAS in patients with KRAS G12C–mutated non–small cell lung cancer, says Sandip P. Patel, MD.
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Sandip P. Patel, MD, an expert on lung cancer
Sandip P. Patel, MD, an expert on lung cancer
Related Content